The current evidence regarding the efficacy of tezepelumab administered for asthma on T2-related comorbidities
Tezepelumab treatment showed undeniable benefits on CRSwNP and AERD by improving sino-nasal and asthma outcomes. If the efficacy of tezepelumab on severe allergic asthma is well documented, current data are insufficient to conclude on its impact on AR. The effects of tezepelumab on AD and CSU were disappointing. No consistent data exists regarding FA and EE. Future studies are needed to confirm the efficacy of tezepelumab on AR, FA, and EE.
Authors
- Angelica I. Tiotiu (ORCID: https://orcid.org/0000-0002-8038-9559)
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- UCLouvain Saint-Louis Brussels (BE)
- Hôpital Saint-Luc (CA)
- UCLouvain (BE)
Publication Details
- Journal
- Expert Review of Respiratory Medicine
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1080/17476348.2025.2600110
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00